Neuvotion
Private Company
Funding information not available
Overview
Neuvotion is a private, pre-revenue biotech founded in 2018, pioneering a novel category of AI-guided brain-body interface (BBI) therapeutics for neurorehabilitation. Their core technology platform, NeuStim, integrates high-resolution neurostimulation with AI to maximize recovery of motor and sensory functions. The company is positioned to address a massive and growing outpatient rehabilitation market, backed by a seasoned leadership team with deep expertise in medical devices and neurosurgery. Initial media coverage suggests promising early clinical validation, though the technology remains in development.
Technology Platform
AI-guided Brain-Body Interface (BBI) platform combining minimally invasive brain-computer interface (BCI) with non-invasive high-resolution spinal/body neurostimulation in a closed-loop system to restore motor and sensory function.
Opportunities
Risk Factors
Competitive Landscape
Neuvotion is pioneering a novel therapeutic BBI category, so direct competitors are limited. It competes indirectly with traditional rehabilitation devices, functional electrical stimulation (FES) systems, and emerging rehabilitative BCIs from companies like Onward Medical. Its main competition is the entrenched standard of care, which it must demonstrably outperform.